Akston Biosciences is building upon its Fc-fusion drug platform to develop market-share-
cornering new drugs and vaccines. Entering phase 3 clinical development in the EU and
India is AKS-452, a potentially universal pandemic-ending COVID vaccine suitable for use
the world over. Next year the company will begin clinical and business development of
its human diabetes products, which include a possible cure for Type I Diabetes in
children, and a market transforming smart, once-weekly insulin for Type 1 & 2 diabetics.
The ultra-long-lasting insulins are already licensed for veterinary applications and are in
later stages of clinical development in dogs and cats.
Levisense is creating and commercializing revolutionary medical beds that sense and
control pressure and air flow for the prevention and treatment of bed sores. This new
medical mattress technology that is expected to transform the high-end medical
bedding market. The LeviSense SensorCell technology interrogates and controls the
patient-bed interface to prevent bed sores from forming, or to heal existing bed sores.
NonExomics is a computational biology-driven discoverer of nonexomic causes,
treatments and cures for hundreds of rare and inherited diseases and numerous
cancers. The nonexomic region of the human genome is barren of conventional genes
and therefore has been believed to not be contributing to disease. NonExomics
researchers discovered that mutations within this region are leading to the manufacture
of proteins that appear to be causing or enhancing a host of rare and inherited diseases
and cancers. These newly discovered proteins have never been drugged, and they may
explain why a host of genetic disorders are incurable or of unknown etiology.
Cell IDx’s primary business is focused on the discovery and commercialization of
biological and organic tools for the life science research and clinical diagnostic markets.
Their initial entrants have been kits and reagents for the pathology slide-staining
market. The kits are superior to current competitors in terms of performance, speed,
and ease of use.
NeuroDex accurately detects neurological diseases and provides monitoring through
simple blood assays. Displaces painful cerebral spinal taps and brain biopsies. It has
developed and is commercializing a technology to rapidly extract neurologically-derived
exosomes from blood. Exosomes are made in large numbers by all human cells on a
daily basis. Diseased cells emit exosomes that carry the signature of their disease. Thus,
nearly all neurological diseases and disorders can be diagnosed and potentially treated
or cured by leveraging the NeuroDex technology. This new approach is rapidly being
adopted by pharma companies for clinical trials.